Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Anbio Biotechnology Class A (NNNN) AI Stock Analysis

62 Followers
NNNN

Anbio Biotechnology Class A

(NASDAQ:NNNN)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Negative Factors

Anbio Biotechnology Class A (NNNN) vs. SPDR S&P 500 ETF (SPY)

-100%-75%-50%-25%0%25%50%75%NNNN-84.44%SPY+14.28%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$177.76M
Dividend Yield
―
Average Volume (3M)
151.01K
Price to Earnings (P/E)
20.9
Beta (1Y)
1.58
Revenue Growth
10.10%
EPS Growth
170.13%
Country
US
Employees
27
Sector
General
Sector Strength
55
Industry
Medical - Instruments & Supplies

Anbio Biotechnology Class A Business Overview & Revenue Model

Company Description

Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, Nor...

Anbio Biotechnology Class A Risk Analysis

Anbio Biotechnology Class A disclosed 40 risk factors in its most recent earnings report. Anbio Biotechnology Class A reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Anbio Biotechnology Class A Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

NNNN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AZTAAZTA63Neutral$1.77B-13.51-10.81%―4.65%-196.27%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
RGENRGEN54Neutral$11.12B-822.00-0.56%―13.80%-811.00%
OSUROSUR43Neutral$229.93M-5.16-15.17%―-7.53%14.93%
QDELQDEL37Underperform$790.42M-2.19-20.13%―-4.64%68.20%

* General Sector Average

Performance Comparison

-50%0%50%NNNNAZTAOSURQDELRGENDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
NNNN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
NNNNAnbio Biotechnology Class A4.05-19.26-82.63%
AZTAAzenta, Inc.48.9019.0263.65%
OSUROrasure3.561.2856.14%
QDELQuidelortho Corporation11.91-10.27-46.30%
RGENRepligen172.6222.0614.65%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.